SSAT Annual Meeting SSAT Annual Meeting

Back to SSAT Site
Annual Meeting Home
SSAT Program and Abstracts
Ticketed and Highlighted Sessions
Other Meetings of Interest
Past & Future Meetings
Photo Gallery

Back to 2017 Program and Abstracts

Juan-Carlos Molina*, Alreem Al Hinai, Alexandre Gosselin-Tardif, Carmen L. Mueller, Jonathan Spicer, David Mulder, Lorenzo E. Ferri
McGill University Health Centre, Montreal, QC, Canada

Curative intent treatment for locally advanced esophagogastric cancer requires complete surgical resection with negative margins. For clinically T4b tumors with adhesion to adjacent organs, a multivisceral en-bloc resection is required to achieve this. However, the oncologic benefit of such major operations has been brought into question, particularly given a perceived unacceptable morbidity for patients with such high disease burden. Prior studies on this topic were hampered by historical data from an era in which chemotherapy was largely ineffective with low response rates. We thus sought to investigate the surgical and oncologic outcomes of en-bloc multivisceral resections for locally advanced gastric and esophagogastric junction (EGJ) carcinomas from a modern era cohort.
Material and Methods
A prospective North American institutional upper GI cancer database was queried from 2005 to 2015. We identified 515 patients who underwent resection for EGJ and gastric cancer, 140 of which had resections of organs in addition to the stomach and esophagus. For the purpose of this study, we included only patients who underwent curative intent en-bloc resection of adjacent organs for cT4b lesions. Clinicopathologic, perioperative and oncologic variables were assessed. Primary outcomes were perioperative complications, mortality, and overall survival. Cox proportional hazards model and multivariate logistic regression were employed. Data presented as Median(IQR).
35 patients were included. Clinicopathologic and clinical data are presented in Table 1. The most common resected organs were pancreas (17, 49%), spleen (12, 34%) and liver (10, 29%). More than one organ other than stomach/esophagus were resected in 15(43%). Although all tumors were adherent to resected organs, in only 14 (42%), the final pathology confirmed organ invasion (pT4b). R0 resection rate was 94% (33). The majority (28, 80%) had lymph node involvement with a high nodal disease burden (positive/resected lymph nodes = 9(2-14)/33(19-47)). Postoperative complications occurred in 16(46%), 10 of which were Clavien-Dindo >2 (anastomotic leak (3, 9%) duodenal stump and pancreatic leak (3, 9%), bile leak, (2, 6%) enterocutaneous fistula (2, 6%)). LOS was 10 days (7-20) and 90-day mortality 0%. 1, 3, and 5-year survival was 82, 47 and 31%. On multivariate analysis, tumor size greater than 7 cm, lymph node involvement, and residual tumor after resection were independently associated with lower survival.
Multivisceral extended resections for esophagogastric cancer can achieve good long-term survival given the high burden of disease and is associated with an acceptable morbidity. R0 resection should be should remain the ultimate goal for the curative intent treatment for locally advanced gastric and EGJ carcinomas even if the tumor is adherent to adjacent organs.

Clinical and Pathologic outcomes
Age (Mean, IQR) 64.5 (59-75) 
SurgeryEsophagectomy/proximal gastrectomy1131
 Total gastrectomy1440
 Extended total gastrectomy/esophagectomy26
 Subtotal gastrectomy823
N organs resected other than esophagus/stomachSingle2057
Organs resectedPancreas17 
 others (Colon, lung, adrenal)18 
pathologic TT31646
pathologic lymph nodesN0720
Postoperative outcomes90-day mortality00
ComplicationsNo complication1954
 Clavien-Dindo I-II617
 Clavien-Dindo IIIa411
 Clavien-Dindo IIIb411
 Clavien-Dindo IVa26
 Total Complications1646

Table 2: Cox Univariate and Multivariate Regression Hazard Models
Feature Cox Univariate Regression Model, HR (95% CI)p valueCox Multivariate Regression Model, HR (95% CI)
p value
Sex 1.4 (0.45-4.3)
Age >65 1.09 (0.41-2.9)
Multiple organs
 1.58 (0.85-2.94)
0.14 0.3
 Pancreas2.2 (0.80-6.04)
0.125 0.31
 Spleen1.92 (0.72-5.14)
 Lung0.85 (0.24-2.99)
 Other1.13 (0.32-4.02)
Tumor Size (cm) 1.23 (1.04-1.45)
0.01 0.05
 Tumor size>7cm
2.52 (0.87-7.31)
0.093.28 (0.99-10.8)
Pathologic T stage 1.09 (0.65-1.84)
Lymph node involvement 11.5 (1.43-93.25)
0.0239.4 (2.84-545.6)
Extent of resection (R1-2 vs 0) 1.77 (0.39-7.93)
0.456.6 (1.53-28.34)

Back to 2017 Program and Abstracts

© 2018 Society for Surgery of the Alimentary Tract. All Rights Reserved. Read the Privacy Policy.